Abstract
A unilateral, apparently sporadic pheochromocytoma was removed from the right adrenal of a 73-yr-old Caucasian woman. At the time of surgery, germline DNA from the patient was not available. However, a continuous cell line (KNA) established from the tumor showed a heterozygous sequence variant TGC (cysteine) to TGG (tryptophan) in exon 10, codon 611 of the RET proto-oncogene. Subsequent genetic testing of the patient and her offspring revealed the same base-change in herself, one daughter, one son, and the only grandson, confirming hereditary disease classified as MEN2A-2. Clinical follow up of the patient revealed elevated serum calcitonin after 6 yr. Thyroidectomy was performed and revealed a small medullary thyroid carcinoma. The patient’s children thus far show no evidence of MEN2, but C-cell hyperplasia has been diagnosed in the grandson. Our serendipitous finding of a MEN2A-2 mutation in a patient with initial diagnosis of late onset, unilateral, “sporadic” pheochromocytoma would argue for routine mutation screening of even elderly patients presenting with a pheochromocytoma.
Similar content being viewed by others
References
Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466, 2002.
Pfragner R, Behmel A, Smith DP, et al. First continuous human pheochromocytoma cell line: KNA. Biological, cytogenetic and molecular characterization of KNA cells. J Neurocytol 27:175–186, 1998.
Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575–1579, 1996.
Ponder BAJ. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res 59:1736–1741, 1999.
Eng C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung’s disease. Seminars in Medicine of the Beth Israel Hospital, Boston 335:943–951, 2003.
Fink M, Weinhäusel A, Niederle B, Haas OA. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. Study Group Multiple Endocrine Neoplasia Austria (SMENA). Int J Cancer 69:312–316, 1996.
Pomares FJ, Canas R, Rodriguez JM, Hernandez AM, Parilla P, Tebar FJ. Differences between sporadic and multiple endocrine neoplasia type 2 pheochromocytoma. Clin Endocrinol 48:195–200, 1998.
Lecube A, Hernandez C, Oriola J, et al. Pheochromocytoma associated with multiple endocrine neoplasia 2A and sporadic: differential characteristics. Med Clin (Barc) 7:405–409, 2000.
Eng C, Mulligan LM. Mutation of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mut 9:97–109, 1997.
Hofstra RM, Stelwagen T, Stulp RP, et al. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. J Clin Endocrinol Metab 81:2881–2884, 1996.
Takaya K, Yoshima T, Arai H, et al. The RET proto-oncogene in sporadic pheochromocytomas. Intern Med 35:339–452, 1996.
Iyengar, S, Tallini G, Surugo G, Bale AE, Kidd KK. Mutation of the VHL gene in individuals with sporadic and familial pheochromocytoma. Am J Hum Genetics 57(Suppl. A67):357, 1995.
Eng C, Crossey PA, Mulligan LM, et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic pheochromocytomas. J Med Genet 32:934–937, 1995.
Brauch H, Höppner W, Jahnig H, et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret proto-oncogene. J Clin Endocrinol Metab 82,:4101–4104, 1997.
Rodien P, Jeunemaitre X, Dumont C, Beldjord C, Plouin PF. Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas. Horm Res 47:263–268, 1997.
van der Harst E, de Krijger RR, Bruining HA, et al. Prognostic value of RET proto-oncogene point mutations in malignant and benign, sporadic pheochromocytomas. Int J Cancer 79:537–540, 1998.
Bender BU, Gutsche M, Glasker S, et al. Different genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytomas. J Clin Endocrinol Metab 85:4568–4574, 2000.
Edstrom E, Frisk T, Farnebo F, Hoog A, Backdahl M, Larsson C. Expression analysis of RET and the GDNF/GFRalpha-1 and NTN/Gfalpha-2 ligand complexes in pheochromocytomas and paragangliomas. Int J Mol Med 6:469–474, 2000.
Matias-Guiu X, Colomer A, Mato E, et al. Expression of the ret proto-oncogene in pheochromocytoma. An in situ hybridization and northern blot study. J Pathol 176:63–68, 1995.
Inabnet WB, Caragliano P, Pertsemlidis D. Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. Surgery 128:1007–1012, 2000.
Casanova S, Rosenberg-Bourgin M, Farkas D, et al. Pheochromocytoma in multiple endocrine neoplasia type 2A: a survey of 100 cases. Clin Endocrinol 38:531–537, 1993.
Modigliani E, Vasen HM, Raue K, et al. and The Euromen Study Group. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. J Intern Med 238:363–367, 1995.
Neumann H, Berger D, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329:1531–1539, 1993.
Conte-Devolx B, Nguyen L, Niccoli-Sire P. Pheochromocytoma in multiple endocrine neoplasia type 2: diagnosis and treatment. Seventh International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, 1999, pp. 119–122.
Nguyen L, Nicoli-Sire P, Caron P, et al. and The French Calcitonin Tumors Study Group. Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. Eur J Endocrinol 144:37–44, 2001.
Frank-Raue K, Kratt T, Höppner TW, Buhr H, Ziegler R, Raue F. Diagnosis and management of pheochromocytoma in patients with multiple endocrine neoplasia type 2—relevance of specific mutations in the RET proto-oncogene. Eur J Endocrinol 135:222–225, 1996.
Heshmati HM, Gharib H., Khosla S, Abu-Lebdeh HS, Lindor NM, Thibodeau SN. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. Mayo Clin Proc 72:430–436, 1997.
Höppner W, Ritter MM. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 6:587–590, 1997.
Höppner W, Dralle H, Brabant G. Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A. Hum Mutation (Supplement 1):128–130, 1998.
Berndt I, Reuter M, Saller B, et al. A new hot spot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770–774, 1998.
Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 17:380–393, 1999.
Tessitore A, Sinis AA, Pasquali D, et al. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET proto-oncogene. J Clin Endocrinol Metab 84:3522–3527, 1999.
Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, Höppner W (2000) A RET double mutation in the germline of a kindred with FMTC. Exper Clin Endocrinol Diabetes 108:128–132
Koch CA, Huang SC, Vortmeyer AO, Zhuang Z, Chrousos GP, Pacak K. A patient with MEN 2 and multiple mutations of RET in the germline. Exper Clin Endocrinol Diabetes 108:493, 2000.
Smith DP, Houghton C, Ponder B. Germline mutation of RET codon 883 in two cases of de novo MEN2B. Oncogene 15:1213–1217, 1997.
Huang SC, Koch CA, Vortmeyer AO, et al. Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2 associated pheochromocytomas. Cancer Res 60:6223–6226, 2000.
Eng C, Mulligan LM, Smith DP, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43:123–127, 1995.
Donis-Keller H. The RET proto-oncogene and cancer. J Intl Med 238:310–325, 1955.
Carlomagno F, Mellilo RM, Visconti R, et al. GDNF differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung’s disease. Endocrinology 139:3613–3619, 1988.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weinhäusel, A., Behmel, A., Ponder, B.A.J. et al. Long-term follow up of a “sporadic” unilateral pheochromocytoma revealing multiple endocrine neoplasia MEN2A-2 in an elderly woman. Endocr Pathol 14, 375–382 (2003). https://doi.org/10.1385/EP:14:4:375
Issue Date:
DOI: https://doi.org/10.1385/EP:14:4:375